SDM for Stroke Prevention in Atrial Fibrillation (SDM4Afib)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02905032 |
Recruitment Status :
Enrolling by invitation
First Posted : September 19, 2016
Last Update Posted : August 6, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Atrial Fibrillation | Behavioral: Decision Aid | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 2700 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Other |
Official Title: | Shared Decision Making for Stroke Prevention in Atrial Fibrillation (SDM4Afib): A Randomized Trial |
Actual Study Start Date : | September 1, 2016 |
Estimated Primary Completion Date : | September 2021 |
Estimated Study Completion Date : | September 2021 |

Arm | Intervention/treatment |
---|---|
No Intervention: Standard Care
Observations in clinical encounter via video, audio or observational notes.
|
|
Active Comparator: Standard Care + Decision Aid
Observation of clinical encounter using the decision aid via video, audio, or observational notes.
|
Behavioral: Decision Aid
Observation of clinical encounter using the electronic decision aid to facilitate treatment option conversation between clinician and patient.
Other Name: DA |
- SDM Quality - Knowledge Transfer, Knowledge of Risk, Collaborative Agreement, Patient decision satisfaction, Quality of communication, Patient satisfaction with encounter, Clinician satisfaction. [ Time Frame: After end of enrollment (1 month) ]SDM quality will measure (a) knowledge transfer; (b) concordance; (c) quality of communication and satisfaction with shared decision making; and (d) satisfaction with the decision-making process. Knowledge Transfer-6 questions about afib and anticoagulation. Knowledge of Risk-1 question about risk of stroke. Collaborative Agreement-will assess decision concordance between patient and clinician. Patient decision satisfaction-16 items of Decisional Conflict Scale. Quality of communication- modified questions from the CAHPS Clinician and Group survey. Patient satisfaction with encounter- asking patients whether they would recommend the approach used to others for other discussions. Clinician satisfaction- questioning satisfaction with discussion about anticoagulation medication choice and whether they would recommend the approach used to other clinicians for other discussions.
- SDM Processes [ Time Frame: After end of enrollment (1 month) ]SDM processes will be assessed based on the review of video/audio or audio only recordings of the clinical encounter.
- Anticoagulation Use [ Time Frame: 12 months post enrollment completion ]Anticoagulation start and continuation rates will be calculated along with percent of days covered based off pharmacist reporting patient fill rates.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Clinician Inclusion Criteria:
• All clinicians (MDs, NP/PAs, PharmDs) that are responsible for the modality of Anticoagulation in eligible AF patients at participating sites, without exclusion
Patient Inclusion Criteria:
- ≥ 18 years of age
- Chronic nonvalvular atrial fibrillation deemed at high risk of thromboembolic strokes (CHA2D2-VASc Score ≥ 1, or 2 in women)
- Able to read and understand (despite cognitive, sensorial, hearing or language challenges) the informed consent document as determined by the study coordinator during consent
Patient Exclusion Criteria:
• Clinician indicates that patient is not a candidate for a discussion about anticoagulation medication

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02905032
United States, Alabama | |
University of Alabama | |
Birmingham, Alabama, United States, 35294 | |
United States, Minnesota | |
Hennepin County Medical Center | |
Minneapolis, Minnesota, United States, 55415 | |
Mayo Clinic in Rochester | |
Rochester, Minnesota, United States, 55905 | |
Park Nicollet Health Partners | |
Saint Louis Park, Minnesota, United States, 55416 | |
United States, Mississippi | |
University of Mississippi Medical Center | |
Jackson, Mississippi, United States, 39216 |
Principal Investigator: | Peter A Noseworthy | Mayo Clinic |
Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Peter A. Noseworthy, M.D., M.D., Mayo Clinic |
ClinicalTrials.gov Identifier: | NCT02905032 |
Other Study ID Numbers: |
16-005409 1R01HL131535 ( U.S. NIH Grant/Contract ) |
First Posted: | September 19, 2016 Key Record Dates |
Last Update Posted: | August 6, 2020 |
Last Verified: | August 2020 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Afib Atrial fib Shared Decision |
Making Aid AF |
Atrial Fibrillation Arrhythmias, Cardiac Heart Diseases Cardiovascular Diseases Pathologic Processes |